Vertex Pharmaceuticals Incorporated
VRTX
$435.52
$1.500.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.99% | 11.28% | 2.59% | 15.66% | 11.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.99% | 12.06% | 2.96% | 15.66% | 11.61% |
| Cost of Revenue | 9.78% | 3.54% | 18.64% | 19.24% | 12.39% |
| Gross Profit | 12.01% | 20.79% | -8.43% | 12.44% | 10.97% |
| SG&A Expenses | 19.71% | 14.08% | 15.67% | 2.30% | 40.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.03% | 5.83% | 17.95% | 15.24% | 17.80% |
| Operating Income | 9.47% | 23.46% | -15.22% | 16.35% | 3.72% |
| Income Before Tax | 6.10% | 137.83% | -42.90% | -0.97% | 3.81% |
| Income Tax Expenses | 20.82% | 23.57% | -53.15% | 25.00% | 24.18% |
| Earnings from Continuing Operations | 3.59% | 128.74% | -41.22% | -5.76% | 0.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.59% | 128.74% | -41.22% | -5.76% | 0.98% |
| EBIT | 9.47% | 23.46% | -15.22% | 16.35% | 3.72% |
| EBITDA | 9.12% | 21.94% | -14.98% | 13.00% | 4.56% |
| EPS Basic | 4.56% | 128.90% | -40.93% | -5.69% | 0.97% |
| Normalized Basic EPS | 10.43% | 20.13% | -15.19% | 9.43% | -0.14% |
| EPS Diluted | 4.74% | 128.66% | -40.86% | -5.64% | 1.01% |
| Normalized Diluted EPS | 10.85% | 19.11% | -15.09% | 9.51% | -0.29% |
| Average Basic Shares Outstanding | -0.93% | -0.54% | -0.50% | -0.08% | 0.00% |
| Average Diluted Shares Outstanding | -1.30% | 0.31% | -0.61% | -0.15% | 0.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |